- Home
- PSF vs TCRX Comparison
PSF vs TCRX Comparison
Compare PSF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- TCRX
- Stock Information
- Founded
- PSF 2010
- TCRX 2018
- Country
- PSF United States
- TCRX United States
- Employees
- PSF N/A
- TCRX N/A
- Industry
- PSF Investment Managers
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- TCRX Health Care
- Exchange
- PSF Nasdaq
- TCRX Nasdaq
- Market Cap
- PSF 246.0M
- TCRX 257.5M
- IPO Year
- PSF N/A
- TCRX 2021
- Fundamental
- Price
- PSF $20.15
- TCRX $4.41
- Analyst Decision
- PSF
- TCRX Strong Buy
- Analyst Count
- PSF 0
- TCRX 5
- Target Price
- PSF N/A
- TCRX $11.40
- AVG Volume (30 Days)
- PSF 25.0K
- TCRX 261.6K
- Earning Date
- PSF 01-01-0001
- TCRX 11-12-2024
- Dividend Yield
- PSF 7.69%
- TCRX N/A
- EPS Growth
- PSF N/A
- TCRX N/A
- EPS
- PSF N/A
- TCRX N/A
- Revenue
- PSF N/A
- TCRX $9,362,000.00
- Revenue This Year
- PSF N/A
- TCRX N/A
- Revenue Next Year
- PSF N/A
- TCRX $3.10
- P/E Ratio
- PSF N/A
- TCRX N/A
- Revenue Growth
- PSF N/A
- TCRX N/A
- 52 Week Low
- PSF $16.00
- TCRX $3.73
- 52 Week High
- PSF $20.19
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- PSF 34.31
- TCRX 34.37
- Support Level
- PSF $20.40
- TCRX $5.03
- Resistance Level
- PSF $21.10
- TCRX $6.23
- Average True Range (ATR)
- PSF 0.20
- TCRX 0.43
- MACD
- PSF -0.04
- TCRX -0.05
- Stochastic Oscillator
- PSF 10.75
- TCRX 5.22
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.